Michael P. Weiner
Fondateur chez Abbratech, Inc.
Profil
Michael P.
Weiner is the founder who has founded Affomix Corp.
in 2006, GnuBIO, Inc. in 2008, AxioMx, Inc. in 2012, and Abbratech, Inc. in 2020 where he currently serves as the Chief Executive Officer & Director.
He held former positions as Director at Rothberg Institute, Inc. from 2002 to 2006, Vice President-Molecular Sciences at RainDance Technologies, Inc. and 454 Life Sciences Corp., and Head-Genomic Sciences Department at GlaxoSmithKline, Inc. Dr. Weiner received a doctorate from Cornell University and an undergraduate degree from The Pennsylvania State University.
Postes actifs de Michael P. Weiner
| Sociétés | Poste | Début |
|---|---|---|
Abbratech, Inc.
 Abbratech, Inc. BiotechnologyHealth Technology Abbratech, Inc. is a biotechnology company that focuses on precision antibodies. Abbratech is based in Branford, CT. The company offers services such as antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Abbratech uses the best available in vivo and in vitro methods for antibody discovery and applies knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. The company was founded in 2020 by Michael P. Weiner, who has been the CEO since then. | Fondateur | 01/01/2020 |
Anciens postes connus de Michael P. Weiner
| Sociétés | Poste | Fin |
|---|---|---|
Affomix Corp.
 Affomix Corp. Pharmaceuticals: MajorHealth Technology Affomix Corp. was develops and commercializes antibody based products. The company was founded in 2008 and headquartered in Branford, CT. | Fondateur | 01/01/2012 |
| Rothberg Institute, Inc. | Directeur/Membre du Conseil | 01/01/2006 |
AxioMx, Inc.
 AxioMx, Inc. Pharmaceuticals: MajorHealth Technology AxioMx, Inc. develops and produces recombinant antibody technologies. Its service offerings include antigen & project design, recombinant antibody development, antibody optimization, and antibody production. The company was founded by Christopher K. McLeod and Michael P. Weiner in 2012 and is headquartered in Branford, CT. | Fondateur | - |
GnuBIO, Inc.
 GnuBIO, Inc. Medical SpecialtiesHealth Technology GnuBIO, Inc. develops life science research and clinical diagnostics products. It develops a droplet-based DNA sequencing technology that integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing to informatics for researchers and clinicians. The company was founded by David A. Weitz, John J. Boyce, IV and Michael P. Weiner and is headquartered in Cambridge, MA. | Fondateur | - |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formation de Michael P. Weiner
| Cornell University | Doctorate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
RainDance Technologies, Inc.
 RainDance Technologies, Inc. Medical SpecialtiesHealth Technology RainDance Technologies, Inc. engages in the development and commercialization of professional laboratory system. It develops and manufactures genomic tools for non-invasive liquid biopsy applications for the research, early detection, treatment of cancer, and inherited and infectious diseases. The company was founded by Andrew Griffiths, Darren R. Link, and Jerome Bibette in 2004 and is headquartered in Billerica, MA. | Health Technology |
454 Life Sciences Corp.
 454 Life Sciences Corp. Medical/Nursing ServicesHealth Services 454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT. | Health Services |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
| Rothberg Institute, Inc. | |
Affomix Corp.
Affomix Corp. Pharmaceuticals: MajorHealth Technology Affomix Corp. was develops and commercializes antibody based products. The company was founded in 2008 and headquartered in Branford, CT. | Health Technology |
GnuBIO, Inc.
GnuBIO, Inc. Medical SpecialtiesHealth Technology GnuBIO, Inc. develops life science research and clinical diagnostics products. It develops a droplet-based DNA sequencing technology that integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing to informatics for researchers and clinicians. The company was founded by David A. Weitz, John J. Boyce, IV and Michael P. Weiner and is headquartered in Cambridge, MA. | Health Technology |
AxioMx, Inc.
AxioMx, Inc. Pharmaceuticals: MajorHealth Technology AxioMx, Inc. develops and produces recombinant antibody technologies. Its service offerings include antigen & project design, recombinant antibody development, antibody optimization, and antibody production. The company was founded by Christopher K. McLeod and Michael P. Weiner in 2012 and is headquartered in Branford, CT. | Health Technology |
Abbratech, Inc.
Abbratech, Inc. BiotechnologyHealth Technology Abbratech, Inc. is a biotechnology company that focuses on precision antibodies. Abbratech is based in Branford, CT. The company offers services such as antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Abbratech uses the best available in vivo and in vitro methods for antibody discovery and applies knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. The company was founded in 2020 by Michael P. Weiner, who has been the CEO since then. | Health Technology |
